Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
TrumpRx looks to gain drug prices comparable to other developed countries through deals with pharma companies on blockbuster drugs.
read more
Pilavapadin uses the novel target of neurotransmitters involved in pain signaling rather than opiate pathways.
read more
Funds will enable the company to initiate phase 3 trials of CX11 in the U.S. and progress with its programs for ischemic stroke and hypertension.
read more
The cuts are the latest in a round of layoffs as the company reprioritizes its resources and launches an “efficiency program.”
read more
Data from phase 1 show efficacy in patients who are resistant to dupilumab and JAK inhibitors.
read more
The company plans to submit a marketing authorization application for daridorexant in South Korea in the first quarter of 2026.
read more
The market will reach $13.1 billion by 2035, fueled by shifting consumer behavior toward preventive health care and non-prescription sleep aids.
read more
The FDA has determined that Travere needs to further characterize the clinical benefit of the oral, non-immunosuppressive therapy to gain approval.
read more
With many Americans struggling to afford health care, Walmart is taking action.
read more
NP-G2-044 has shown efficacy in blocking metastasis and, combined with immune checkpoint inhibitors, is effective at reinvigorating anti-tumor responses.
read more
The first-of-its-kind co-innovation lab will focus on applying AI to tackle some of the most enduring challenges in drug discovery.
read more
Lilly will pick up clinical stage NLRP3 inhibitors in an all-cash $1.2 billion deal.
read more
The oral medication was approved in December based on phase 3 trial results that showed an average weight loss of 17%.
read more
Three clinical trials on patients with histories of motion sickness showed that the treatment significantly reduced vomiting compared with a placebo.
read more
Although the drug met its primary endpoint in a clinical trial, the FDA wants additional proof of effectiveness.
read more